Avidity Biosciences (RNA) Operating Expenses (2019 - 2025)
Historic Operating Expenses for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $201.3 million.
- Avidity Biosciences' Operating Expenses rose 10033.94% to $201.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $633.3 million, marking a year-over-year increase of 8916.06%. This contributed to the annual value of $389.8 million for FY2024, which is 5901.3% up from last year.
- Latest data reveals that Avidity Biosciences reported Operating Expenses of $201.3 million as of Q3 2025, which was up 10033.94% from $175.0 million recorded in Q2 2025.
- Over the past 5 years, Avidity Biosciences' Operating Expenses peaked at $201.3 million during Q3 2025, and registered a low of $26.6 million during Q1 2021.
- Moreover, its 5-year median value for Operating Expenses was $59.8 million (2023), whereas its average is $76.8 million.
- In the last 5 years, Avidity Biosciences' Operating Expenses surged by 25376.93% in 2021 and then soared by 1335.27% in 2023.
- Over the past 5 years, Avidity Biosciences' Operating Expenses (Quarter) stood at $40.4 million in 2021, then surged by 38.6% to $56.0 million in 2022, then rose by 23.11% to $68.9 million in 2023, then surged by 79.82% to $124.0 million in 2024, then skyrocketed by 62.37% to $201.3 million in 2025.
- Its Operating Expenses was $201.3 million in Q3 2025, compared to $175.0 million in Q2 2025 and $133.1 million in Q1 2025.